老虎證券

BRIEF-European Commission Approves Johnson & Johnson’S Subcutaneous Darzalex® (Daratumumab)-Based Quadruplet Regimen

Reuters
2025/04/07
BRIEF-European Commission Approves Johnson & Johnson’S Subcutaneous Darzalex® (Daratumumab)-Based Quadruplet Regimen

April 7 (Reuters) - Johnson & Johnson JNJ.N:

  • EUROPEAN COMMISSION APPROVES JOHNSON & JOHNSON’S SUBCUTANEOUS DARZALEX® (DARATUMUMAB)-BASED QUADRUPLET REGIMEN FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA, REGARDLESS OF TRANSPLANT ELIGIBILITY

Source text: [ID:]

Further company coverage: JNJ.N

((Reuters.Briefs@thomsonreuters.com;))

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10